Open22.470 | Close21.540 |
Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
Open22.470 | Close21.540 |
Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
REV | 17.490M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.420 | -1.080 | 0.3400 | ||||
REV | 18.050M | 20.116M | 2.066M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BEAM | Beam Therapeutics | -3.75% | 1.7B |
IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
ZNTL | Zentalis Pharma | 3.11% | 1.4B |
PRTA | Prothena Corp | -4.65% | 2.4B |
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Beam Therapeutics.
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
Open22.470 | Close21.540 |
Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
REV | 17.490M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.420 | -1.080 | 0.3400 | ||||
REV | 18.050M | 20.116M | 2.066M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BEAM | Beam Therapeutics | -3.75% | 1.7B |
IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
ZNTL | Zentalis Pharma | 3.11% | 1.4B |
PRTA | Prothena Corp | -4.65% | 2.4B |
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Beam Therapeutics.
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
Open22.470 | Close21.540 |
Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
REV | 17.490M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.420 | -1.080 | 0.3400 | ||||
REV | 18.050M | 20.116M | 2.066M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BEAM | Beam Therapeutics | -3.75% | 1.7B |
IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
ZNTL | Zentalis Pharma | 3.11% | 1.4B |
PRTA | Prothena Corp | -4.65% | 2.4B |
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Beam Therapeutics.
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
Open22.470 | Close21.540 |
Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
REV | 17.490M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.420 | -1.080 | 0.3400 | ||||
REV | 18.050M | 20.116M | 2.066M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BEAM | Beam Therapeutics | -3.75% | 1.7B |
IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
ZNTL | Zentalis Pharma | 3.11% | 1.4B |
PRTA | Prothena Corp | -4.65% | 2.4B |
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Beam Therapeutics.
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
Open22.470 | Close21.540 |
Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
REV | 17.490M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.420 | -1.080 | 0.3400 | ||||
REV | 18.050M | 20.116M | 2.066M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BEAM | Beam Therapeutics | -3.75% | 1.7B |
IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
ZNTL | Zentalis Pharma | 3.11% | 1.4B |
PRTA | Prothena Corp | -4.65% | 2.4B |
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Beam Therapeutics.
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
Open22.470 | Close21.540 |
Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
REV | 17.490M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.420 | -1.080 | 0.3400 | ||||
REV | 18.050M | 20.116M | 2.066M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BEAM | Beam Therapeutics | -3.75% | 1.7B |
IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
ZNTL | Zentalis Pharma | 3.11% | 1.4B |
PRTA | Prothena Corp | -4.65% | 2.4B |
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Beam Therapeutics.
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
Open22.470 | Close21.540 |
Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
REV | 17.490M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.420 | -1.080 | 0.3400 | ||||
REV | 18.050M | 20.116M | 2.066M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BEAM | Beam Therapeutics | -3.75% | 1.7B |
IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
ZNTL | Zentalis Pharma | 3.11% | 1.4B |
PRTA | Prothena Corp | -4.65% | 2.4B |
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Beam Therapeutics.
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
Open22.470 | Close21.540 |
Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
REV | 17.490M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.420 | -1.080 | 0.3400 | ||||
REV | 18.050M | 20.116M | 2.066M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BEAM | Beam Therapeutics | -3.75% | 1.7B |
IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
ZNTL | Zentalis Pharma | 3.11% | 1.4B |
PRTA | Prothena Corp | -4.65% | 2.4B |
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Beam Therapeutics.
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Beam Therapeutics Stock (NASDAQ: BEAM) stock price, news, charts, stock research, profile.
Open22.470 | Close21.540 |
Vol / Avg.965.748K / 865.243K | Mkt Cap1.707B |
Day Range21.020 - 22.595 | 52 Wk Range21.020 - 54.020 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.340 | (EXPECTED) 2023-11-06 | |||||
REV | 17.490M |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.420 | -1.080 | 0.3400 | ||||
REV | 18.050M | 20.116M | 2.066M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-29 | Cantor Fitzgerald | Rick Bienkowski | Reiterates | OverweightOverweight | Maintains | - | 56.00 |
2023-08-09 | Barclays | Gena Wang | Maintains | Equal-WeightEqual-Weight | Lowers | 41.00 | 35.00 |
2023-08-09 | Credit Suisse | Richard Law | Maintains | NeutralNeutral | Raises | 46.00 | 47.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BEAM | Beam Therapeutics | -3.75% | 1.7B |
IDYA | IDEAYA Biosciences | -0.16% | 1.5B |
RARE | Ultragenyx Pharmaceutical | -3.44% | 2.4B |
ZNTL | Zentalis Pharma | 3.11% | 1.4B |
PRTA | Prothena Corp | -4.65% | 2.4B |
You can purchase shares of Beam Therapeutics (NASDAQ: BEAM) through any online brokerage.
Other companies in Beam Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Ultragenyx Pharmaceutical (NASDAQ:RARE), Zentalis Pharma (NASDAQ:ZNTL), Prothena Corp (NASDAQ:PRTA) and SpringWorks Therapeutics (NASDAQ:SWTX).
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on Wednesday, September 13, 2023. The analyst firm set a price target for 56.00 expecting BEAM to rise to within 12 months (a possible 159.86% upside). 16 analyst firms have reported ratings in the last year.
The stock price for Beam Therapeutics (NASDAQ: BEAM) is $21.55 last updated October 4, 2023 at 11:33 PM UTC.
A quarterly cash dividend of $0.23 per share of Class A Common Stock. The quarterly cash dividend was payable on March 3, 2014 to stockholders of record on February 4, 2014.
Beam Therapeutics’s Q3 earnings are confirmed for Monday, November 6, 2023.
There is no upcoming split for Beam Therapeutics.
Beam Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.